The ORIENT-32 study is a randomized, open-label, multi-center, Phase 2/3 trial conducted in China to evaluate the safety and efficacy of sintilimab in combination with IBI305 (a recombinant humanized anti-VEGF monoclonal antibody), compared to sorafenib as first-line treatment in patients with advanced HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.